Drug-eluting-stents for Unprotected Left Main Stem Disease (ISAR-LEFT-MAIN)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

607 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-07-31

Study Completion Date

2008-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy of sirolimus- and paclitaxel-eluting stents for treatment of unprotected left main coronary artery disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Drug-eluting Stents to Treat Unprotected Coronary Left Main Disease

NCT00598637

Coronary Disease

COMPLETED PHASE4

Sirolimus- and Paclitaxel-Eluting Stents for Small Vessels (ISAR-SMART-3)

NCT00146575

Coronary Disease

COMPLETED PHASE4

Nonpolymer- and Polymer-Based Drug-Eluting Stents for Restenosis (ISAR-TEST-1)

NCT00140530

Coronary Disease

COMPLETED PHASE4

The Efficacy of Three Different Limus Agent-Eluting Stents to Prevent Restenosis

NCT00332397

Coronary Disease

COMPLETED PHASE4

Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions

NCT05209412

De Novo Stenosis Coronary Artery Disease Percutaneous Coronary Intervention

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

With the advent of coronary stents and improvements in periprocedural antithrombotic regimen, the spectrum of indications of percutaneous coronary interventions has continuously expanded for patients with coronary heart disease, gaining ground in what have been traditionally considered as domains of coronary bypass surgery. Several groups reported the outcomes of patients with unprotected left main coronary artery (LMCA) disease treated with stenting. Most of them found that LMCA stenting was feasible and safe, and, in low-risk patients, it was associated with minimal periprocedural complications and low long-term morbidity and mortality. Despite these encouraging reports, a widespread use of this technique has been hampered by the still high incidence of restenosis. It is commonly accepted that coronary bypass graft surgery and stenting for unprotected LMCA disease are associated with similar rates of mortality, and that the higher incidence of restenosis and greater need for revascularization procedures after LMCA stenting remain the major contributors for the observed difference in clinical efficacy between both therapies. The recent introduction of stents eluting anti-restenotic drugs, with sirolimus and paclitaxel the most studied compounds, has opened new perspectives for the prevention of restenosis. Several randomized trials have reported excellent results in the reduction of restenosis and need for reinterventions with drug-eluting stents (DES). Although, none of these trials studied the benefit of DES for lesions located in the LMCA, their results suggested that use of these new devices may be particularly helpful for the reduction of restenosis in the group of patients with left main trunk disease. This is supported by the findings of several series of patients with unprotected LMCA disease who have been successfully treated with DES. Importantly, for patients who are unable to undergo CABG due to cardiac surgeons' refusal (poor surgical candidates) or their own unwillingness, stenting with DES remains the only revascularization alternative. Recent guidelines of PCI recommend stenting, preferentially with DES, for unprotected LMCA in the absence of other revascularization options.

Comparison:

Sirolimus-eluting stents compared with paclitaxel-eluting stent for treatment of lesions allocated at left main trunk.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Sirolimus-eluting stent (Cypher)

Group Type ACTIVE_COMPARATOR

Sirolimus-eluting stent

Intervention Type DEVICE

cypher stent is implanted due to randomization.

B

Paclitaxel-eluting stent (Taxus)

Group Type ACTIVE_COMPARATOR

Paclitaxel-eluting stent

Intervention Type DEVICE

taxus stent is implanted due to randomization.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sirolimus-eluting stent

cypher stent is implanted due to randomization.

Intervention Type DEVICE

Paclitaxel-eluting stent

taxus stent is implanted due to randomization.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cypher Taxus

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients older than age 18 with ischemic symptoms or evidence of myocardial ischemia in the presence of ≥50% stenosis located in unprotected LMCA who are unable to undergo coronary artery bypass graft (CABG)
* Pretreatment with a loading dose of 300-600 mg clopidogrel
* Informed, written consent

Exclusion Criteria

* Cardiogenic shock;
* ST-segment elevation acute myocardial infarction within 48 h from symptom onset;
* In-stent restenosis;
* Malignancies or other comorbid conditions with life expectancy less than one year;
* Prior coronary artery bypass surgery with revascularization of left anterior descending (LAD) and/or left circumflex (LCx) coronary artery
* Planned staged percutaneous coronary intervention (PCI) procedure within 30 days from index procedure or prior PCI within the last 30 days
* Left main size \>4.5mm
* An elective surgical procedure is planned during the first six months post enrolment;
* Known allergy to the study medications
* Pregnancy
* Patient's inability to fully cooperate with the study protocol

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No